Tratamiento farmacológico. Psicofármacos

Sáiz Martínez, Pilar Alejandra; García-Portilla González, Mª Paz; Martínez Barrondo, Sara; Bascarán Fernández, Mª Teresa; Paredes Ojanguren, Begoña; Bobes García, Julio.
Adicciones (Palma de Mallorca) ; 16(supl.2): 275-285, 2004. tab
Artículo en Español | IBECS (España) | ID: ibc-136861

Documentos relacionados

  1. Emerging drugs for the treatment of tobacco dependence: 2014 update.
  2. The effects of bupropion alone and combined with naltrexone on blood pressure and CRP concentration: A systematic review and meta-regression analysis of randomized controlled trials.
  3. Naltrexone-bupropion for weight loss.
  4. Advances in non-nicotine pharmacotherapy for smoking cessation.
  5. An open-label trial on the efficacy and tolerability of naltrexone/bupropion SR for treating altered eating behaviours and weight loss in binge eating disorder.
  6. Weight-loss response to naltrexone/bupropion is modulated by the Taq1A genetic variant near DRD2 (rs1800497): A pilot study.
  7. Psychiatric adverse events and effects on mood with prolonged-release naltrexone/bupropion combination therapy: a pooled analysis.
  8. Antidepressant Augmentation versus Switch in Treatment-Resistant Geriatric Depression.
  9. A Preliminary, Open-Label Study of Naltrexone and Bupropion Combination Therapy for Treating Binge Drinking in Human Subjects.
  10. Is there a therapeutic potential in combining bupropion and naltrexone in schizophrenia?